II.studio / Shutterstock.com
19 April 2022Big PharmaMuireann Bolger
Novartis Hepatitis C patent upheld by Delhi High Court
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
5 November 2021 Novartis yesterday, November 4, announced that it is selling its entire stake in Roche—equating to 53.3 million bearer shares—back to the Swiss healthcare company for the sum of $20.7 billion.
Americas
4 May 2021 Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Editor's picks
Editor's picks
Big Pharma
5 November 2021 Novartis yesterday, November 4, announced that it is selling its entire stake in Roche—equating to 53.3 million bearer shares—back to the Swiss healthcare company for the sum of $20.7 billion.
Americas
4 May 2021 Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Big Pharma
5 November 2021 Novartis yesterday, November 4, announced that it is selling its entire stake in Roche—equating to 53.3 million bearer shares—back to the Swiss healthcare company for the sum of $20.7 billion.
Americas
4 May 2021 Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.